Open AccessThis article is
- freely available
Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma
Department of Oncology, Cross Cancer Institute, School of Cancer, Imaging and Engineering Sciences, Faculty of Medicine and Dentistry, University of Alberta, 11560 University Avenue, Edmonton, Alberta, T6G 1Z2, Canada
* Authors to whom correspondence should be addressed.
Received: 5 August 2011; in revised form: 30 August 2011 / Accepted: 8 September 2011 / Published: 14 September 2011
Abstract: The incidence and mortality of pancreas cancer converge. There has been little advancement in the treatment of pancreas cancer since the acceptance of gemcitabine as the standard therapy. Unfortunately, the efficacy of gemcitabine is dismal. While there is much discussion for the development of biomarkers to help direct therapy in this area, there is little action to move them into clinical practice. Herein, we review potential pancreatic cancer biomarkers and discuss the limitations in their implementation.
Keywords: pancreatic adenocarcinoma; hENT1; hCNT3; SPARC; cDK; biomarker; clinical trials; gemcitabine; oxaliplatin
Citations to this Article
Cite This Article
MDPI and ACS Style
Spratlin, J.L.; Mulder, K.E. Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma. Int. J. Mol. Sci. 2011, 12, 5895-5907.
Spratlin JL, Mulder KE. Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma. International Journal of Molecular Sciences. 2011; 12(9):5895-5907.
Spratlin, Jennifer L.; Mulder, Karen E. 2011. "Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma." Int. J. Mol. Sci. 12, no. 9: 5895-5907.